EUCTR2010-019181-91-DE进行中（未招募）1 期
Treatment of High Grade Non-Muscle Invasive Urothelial Carcinoma of the Bladder by Standard Number and Dose of Intravesical BCG Instillations Versus Reduced Number of Intravesical Instillations with Standard Dose of BCG. A European Association of Urology Research Foundation Randomised Phase III Clinical Trial - NIMBUS. - Standard vs Reduced Frequency BCG instillation therapy
EAU Foundation for Urological Research0 个研究点目标入组 824 人开始时间: 2013年5月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 824
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Presence of high grade (Ta-T1) urothelial papillary carcinoma of the bladder with or without CIS
- •1.1. Tumors can be primary or recurrent
- •1.2. Tumors can be single or multiple
- •2a. In case of a Ta high grade tumor in the initial resection, a re-TUR can be performed at the discretion of the investigator. Initial resection or re-TUR must include the deep resection or cold cup biopsy (deep enough to obtain muscle tisssue) of the (initial) tumor site(s)
- •2b. In case of a T1 high grade tumor in the initial resection, a Re-TUR should be performed at weeks 4-8 after initial resection, which must include the deep resection or cold cup biopsy (deep enough to obtain muscle tisssue) of the initial tumor site(s)
- •3. Re-re-TUR should be performed at weeks 4-8 after re-TUR in case of histological detection of T1 low/high grade tumor in the re-TUR, which must include the deep resection or cold cup biopsy (deep enough to obtain muscle tisssue) of the initial tumor site(s)
- •4. Histopathologically confirmed absence of T1 low/high grade tumor(s) in the re-TUR specimen and/or re-re-TUR specimen
- •5. All visible papillary tumors must be completely resected
- •6. If the patient is male, he must use a condom during sexual intercourse during the first week after BCG treatment. If the patient is female, and of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during all study treatment period and for 3 months after the last BCG treatment.
- •7. Signed and dated informed consent form.
- •8. Patient is clinically fit enough to receive BCG bladder instillations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 450
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 550
排除标准
- •1. Any previous intravesical BCG therapy
- •2. Presence of primary CIS only.
- •3. Presence of histopathologically proven muscle invasive urothelial carcinoma of the bladder at first or (re-)re-TUR surgical specimens
- •4. Presence of any tumors in upper urinary tract or in the prostatic urethra at any time
- •5. Presence of any other histological type of resected tumor other than urothelial carcinoma on the first or second resection
- •6. Presence of another malignancy within 5 years except for basal cell carcinoma of the skin or localised prostate cancer in active surveillance
- •7. Presence of pregnancy or lactation
- •8. Presence of active tuberculosis, any form of immunodeficiency (eg HIV + serology, transplant recipients) and/or any other contraindication of BCG therapy
- •9. Patients who have received any systemic cytostatic agents or multi-instillation intravesical chemotherapy in the 3 months prior to randomisation. Early postoperative (within 6 hours of resection) single dose chemotherapy is allowed after the first resection. However, it should not be given after (re-)re-TUR if the patient is considered eligible for this study.
- •10. Patients with uncontrollable UTI
研究者
相似试验
进行中（未招募）
1 期
Standard number and dose intravesical instillation therapy with BCG versus Reduced number and standard dose intravesical instillation therapy with BCG in patients with high grade non-muscle invasive urinary bladder carcinoma.EUCTR2010-019181-91-FREAU Foundation for Urological Research824
进行中（未招募）
3 期
Treatment of High Grade Non-Muscle Invasive Urothelial Carcinoma of the Bladder by Standard Number and Dose of Intravesical BCG Instillations Versus Reduced Number of Intravesical Instillations with Standard Dose of BCG.bladderurothelial carcinomaC67Malignant neoplasm of bladderDRKS00005651European Association of Urology359
进行中（未招募）
1 期
Standard number and dose intravesical instillation therapy with BCG versus Reduced number and standard dose intravesical instillation therapy with BCG in patients with high grade non-muscle invasive urinary bladder carcinoma.on muscle invasive bladder cancer after transurethral resection of the Bladder Tumor (TURT).MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019181-91-BEEAU Foundation for Urological Research824
进行中（未招募）
1 期
Standard number and dose intravesical instillation therapy with BCG versus Reduced number and standard dose intravesical instillation therapy with BCG in patients with high grade non-muscle invasive urinary bladder carcinoma.on muscle invasive bladder cancer after transurethral resection of the Bladder Tumor (TURT).MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019181-91-ESEAU Foundation for Urological Research824
尚未招募
不适用
A single institutional study on clinicopathological profile of early bladder cancerCTRI/2018/11/016426Kasturba Medical College Manipal